Navigation Links
Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals

Cambridge, MA (PRWEB) July 23, 2014

Astra Nova Training, a global provider of innovative and comprehensive consultancy and pharma training services, and the Alliance for Clinical Research Excellence and Safety (ACRES), a non-profit integrating the expertise and investments of research stakeholders worldwide to build and maintain a global system for clinical trials, are pleased to announce a strategic alliance collaboration to improve the expertise of industry professionals through improved and easily available training quality, thus enhancing greater patient safety.

Since its establishment in 2008, UK-based Astra Nova has introduced an international network of over 140 industry experts based in over 50 countries around the globe. In addition, the company has launched over 20 free and commercial online training courses, accessible on their Learning Management System. More than 5,000 professionals worldwide have obtained industry certification through their in-house and online training solutions.

ACRES, a non-profit organization operating in the public interest, is dedicated to enhancing quality, safety, integrity, and operational effectiveness in drug development and health research through the building of a global system for clinical research. To achieve this, ACRES has adopted an Alliance-based model whereby those organizations with a stake in clinical trials being conducted according to the highest standards of safety, quality, and efficiency, are the very organizations that—together—build the comprehensive, integrated system to make such excellence possible.

Astra Nova, with its strong commitment to corporate social responsibility (CSR), will make available interactive and easy-to access online training solutions for ACRES Global Platform of services. This CSR commitment, mirrored by ACRES, is exemplified in Astra Nova’s Better Industry Initiative (Bii), which provides free and commercial high-quality training courses and other resources, with an ultimate goal of better serving patients by equipping future and current industry professionals with more refined skills and workflow efficiency tools.

With Astra Nova, ACRES will provide timely information on critical training topics and materials needed globally, and they will partner on Learning Management Systems development. Other collaborative efforts involve jointly organizing multi-stakeholder events dedicated to improving the conduct of clinical research globally.

Astra Nova’s Business Development Director, Ms. Maya Zlatanova, said: “Our main goal is to improve patient safety and allow easier access to industry regulations, standards, and knowledge. We believe that everyone will benefit from this partnership, and the results of this collaboration will become visible in the very first days of establishing it.”

Dr Matthew Whalen, COO of ACRES, noted, “ACRES work is conducted through alliances, and Astra Nova brings added depth to ACRES network of organizations committed to transforming the world of clinical research.” Whalen added, “We are looking forward to working together with Astra Nova in a variety of ways to realize our shared collaboration goal of providing more innovative solutions, broader standardization, better quality of service, greater safety, and increased efficiency.”


More information on Astra Nova’s work can be found here. For more information, please contact Ms. Maya Zlatanova at maya(at)astranovatraining(dot)co(dot)uk.


More information on the Alliance for Clinical Research Excellence and Safety (ACRES) may be found here. For more information, please contact Dr. Mary F. Tobin at mtobin(at)acresglobal(dot)net.

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Announces Collaboration With AstraZeneca on the Analysis of Compound Combination Experiments
2. New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline
3. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
4. Todays Technical View: AstraZeneca, GlaxoSmithKline, Keryx Biopharma, and Raptor Pharma
5. Top Five Global Cardiovascular Drug Companies 2013 Report Features Players such as Pfizer and AstraZeneca
6. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
7. Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISIS-AR Rx to Treat Prostate Cancer
8. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
9. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
10. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients
11. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
Post Your Comments:
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
(Date:11/24/2015)... ... 24, 2015 , ... The United States Golf Association (USGA) today announced Dr. ... Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... metabolism. But unless it is bound to proteins, copper is also toxic to ... researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper ...
(Date:11/24/2015)... --> --> ... Synthesis Market by Product & Services (Primer, Probe, Custom ... RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - ... is expected to reach USD 1,918.6 Million by 2020 ... of 10.1% during the forecast period. Browse ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
Breaking Biology News(10 mins):